OmniAb (OABI) Liabilities and Shareholders Equity (2021 - 2026)
OmniAb (OABI) reported Liabilities and Shareholders Equity of $293.6 million for Q1 2026, down 4.09% year-over-year from $306.2 million in Q1 2025, and down 2.41% quarter-over-quarter from $300.9 million in Q4 2025.
OmniAb (OABI) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $293.6 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $293.6 million, down 4.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 7.74% YoY), and the FY2025 annual result was $300.9 million, down 7.57% from the prior year.
- Liabilities and Shareholders Equity eased to $293.6 million in Q1 2026 per OABI's latest filing, from $300.9 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $421.2 million in Q4 2022 and troughed at $236.8 million in Q2 2022.
- A 5-year average of $327.7 million and a median of $325.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 37283.13% in 2022, then retreated 16.77% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $421.2 million in 2022, then retreated by 10.92% to $375.2 million in 2023, then declined by 13.24% to $325.6 million in 2024, then declined by 7.57% to $300.9 million in 2025, then slipped by 2.41% to $293.6 million in 2026.
- Business Quant data shows OABI's Liabilities and Shareholders Equity at $293.6 million in Q1 2026, $300.9 million in Q4 2025, and $309.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 293.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293.65 Mn |
| Dec 31, 2025 | 300.91 Mn |
| Sep 30, 2025 | 309.69 Mn |
| Jun 30, 2025 | 295.67 Mn |
| Mar 31, 2025 | 306.18 Mn |
| Dec 31, 2024 | 325.56 Mn |
| Sep 30, 2024 | 331.55 Mn |
| Jun 30, 2024 | 337.26 Mn |
| Mar 31, 2024 | 352.56 Mn |
| Dec 31, 2023 | 375.23 Mn |
| Sep 30, 2023 | 391.71 Mn |
| Jun 30, 2023 | 405.24 Mn |
| Mar 31, 2023 | 413.04 Mn |
| Dec 31, 2022 | 421.21 Mn |
| Sep 30, 2022 | 237.61 Mn |
| Jun 30, 2022 | 236.79 Mn |
| Mar 31, 2022 | 236.90 Mn |
| Dec 31, 2021 | 304.47 Mn |
| Sep 30, 2021 | 236.99 Mn |
| Jun 30, 2021 | 633,415.00 |